Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer

Recruiting

Conditions: Malignant Neoplasm

Interventions: Other: cytology specimen collection procedure

First Posted Date: 2014-10-31

Last Posted Date: 2024-10-08

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 2000

Registration Number: NCT02280161

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Phase 2

Withdrawn

Conditions: Recurrent Melanoma
Stage IV Melanoma

Interventions: Drug: Raf kinase inhibitor LGX818
Drug: binimetinib
Other: laboratory biomarker analysis

First Posted Date: 2014-10-13

Last Posted Date: 2020-07-27

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT02263898

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Predictors of Patient Attitudes and Barriers to Skin Cancer Screening

Completed

Conditions: Skin Cancer

Interventions: Other: Survey

First Posted Date: 2014-09-09

Last Posted Date: 2020-07-27

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1040

Registration Number: NCT02235116

Locations: 🇺🇸
UCLA Dermatology, Los Angeles, California, United States

Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer

Completed

Conditions: Prostate Cancer

Interventions: Device: Laser Interstitial Thermal Therapy

First Posted Date: 2014-08-25

Last Posted Date: 2020-07-27

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 8

Registration Number: NCT02224911

Locations: 🇺🇸
UCLA, Los Angeles, California, United States

Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer

Not Applicable

Active, not recruiting

Conditions: Adenocarcinoma of the Prostate
Stage IIB Prostate Cancer
Stage I Prostate Cancer
Stage IIA Prostate Cancer

Interventions: Behavioral: behavioral dietary intervention
Dietary Supplement: omega-3 fatty acid
Other: laboratory biomarker analysis

First Posted Date: 2014-06-27

Last Posted Date: 2024-10-17

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 107

Registration Number: NCT02176902

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

Conditions: Carcinoid Cancer
Neuroendocrine Tumors
Cancers Expressing Somatostatin Receptors
Medullary Thyroid Cancer

First Posted Date: 2014-06-25

Last Posted Date: 2020-07-27

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT02174679

Locations: 🇺🇸
UCLA Hospital, Los Angeles, California, United States

Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer

Phase 1

Completed

Conditions: Prostate Cancer
Pancreatic Cancer
Bladder Cancer

Interventions: Radiation: [124I] PSCA-Minibody PET/CT imaging of the whole body

First Posted Date: 2014-03-20

Last Posted Date: 2020-07-27

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 8

Registration Number: NCT02092948

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

Phase 1

Terminated

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: cyclophosphamide
Drug: fludarabine phosphate
Biological: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
Biological: dendritic cell vaccine therapy
Biological: aldesleukin
Radiation: fludeoxyglucose F 18
Procedure: positron emission tomography
Other: laboratory biomarker analysis

First Posted Date: 2014-02-25

Last Posted Date: 2019-02-28

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 4

Registration Number: NCT02070406

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor
Metastatic Cancer

Interventions: Drug: PARP inhibitor BMN-673
Drug: temozolomide
Drug: irinotecan hydrochloride
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2014-01-30

Last Posted Date: 2022-09-26

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 44

Registration Number: NCT02049593

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer

Phase 2

Completed

Conditions: Human Papilloma Virus Infection
Stage III Squamous Cell Carcinoma of the Hypopharynx
Stage III Squamous Cell Carcinoma of the Larynx
Stage III Squamous Cell Carcinoma of the Oropharynx
Stage III Verrucous Carcinoma of the Larynx
Stage IV Squamous Cell Carcinoma of the Hypopharynx
Stage IV Verrucous Carcinoma of the Larynx
Stage IVA Squamous Cell Carcinoma of the Larynx
Stage IVA Squamous Cell Carcinoma of the Oropharynx
Stage IVA Verrucous Carcinoma of the Larynx

Interventions: Drug: paclitaxel
Drug: carboplatin
Radiation: intensity-modulated radiation therapy
Procedure: quality-of-life assessment

First Posted Date: 2014-01-29

Last Posted Date: 2018-08-14

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 26

Registration Number: NCT02048020

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy